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Abstract
Activating mutations, such as E76K and D61Y, in PTPN11 (SHP2), a protein tyrosine phosphatase 
implicated in multiple cell signaling processes, are associated with 35% of patients with juvenile 
myelomonocytic leukemia (JMML), an aggressive childhood myeloproliferative neoplasm (MPN). 
Effective therapeutic interventions for this malignancy are still lacking. Here we show that the 
interaction between leukemia-associated mutant Shp2 and Gab2, a scaffolding protein important 
for cytokine-induced PI3K/Akt signaling, was enhanced, and that the mTOR pathway was 
elevated in Ptpn11E76K/+ leukemic cells. Importantly, MPN induced by the Ptpn11E76K/+ mutation 
was markedly attenuated in Ptpn11E76K/+/Gab2−/− double mutant mice — Overproduction of 
myeloid cells was alleviated, splenomegaly was diminished, and myeloid cell infiltration in non-
hematopoietic organs was decreased in these double mutants. Excessive myeloid differentiation of 
stem cells was also normalized by depletion of Gab2. Acute leukemia progression of MPN was 
reduced in the double mutant mice, and as such, their survival was much prolonged. Furthermore, 
treatment of Ptpn11E76K/+ mice with Rapamycin, a specific and potent mTOR inhibitor, mitigated 
MPN phenotypes. Collectively, this study reveals an important role of the Gab2/PI3K/mTOR 
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pathway in mediating the pathogenic signaling of the PTPN11 gain-of-function mutations, and a 
therapeutic potential of Rapamycin for PTPN11 mutation-associated JMML.
INTRODUCTION
Juvenile myelomonocytic leukemia (JMML), an aggressive myeloproliferative neoplasm 
(MPN) of early childhood, is characterized by hypersensitivity of myeloid progenitors to 
cytokines, such as granulocyte-macrophage colony stimulating factor (GM-CSF) 1, 2, and 
overproduction of myeloid cells and monocytes. JMML cells retain capabilities to 
differentiate, but can infiltrate into non-hematopoietic organs, disrupting their functions. 
This disease can progress to acute myeloid leukemia. While the current standard of care for 
patients with JMML relies on allogeneic hematopoietic stem cell (HSC) transplant, relapse 
is the most frequent cause of treatment failure 3–5. New therapeutic interventions are still 
needed for this fatal disease.
Significant progress in understanding the pathogenesis of JMML has been achieved by 
deciphering the genetic lesions that occur in patients. The genetic mutations identified in 
JMML occur in the signaling proteins involved in the RAS/ERK pathway 3–5, providing new 
opportunities for both diagnosis and therapy. Thirty-five percent of patients with JMML 
have mutations, such as E76K and D61Y, in the protein tyrosine phosphatase (PTP) PTPN11 
(SHP2), a positive regulator of the Ras pathway (see below), while activating mutations in 
RAS (K-RAS or N-RAS), homozygous inactivation of NF1, a GTPase activating protein that 
negatively regulates Ras output, and loss-of-function mutations in the E3 ubiquitin ligase c-
CBL account for 20%, 15%, and 10–15% of JMML cases, respectively 6–9. PTPN11, RAS, 
NF1, and c-CBL mutations are usually mutually exclusive in patients. When modeled using 
murine systems, gain-of-function mutations in Ptpn11, K-Ras, and N-Ras, or loss-of-
function in Nf1 and Cbl, are sufficient to induce cytokine hypersensitivity in myeloid 
progenitors and to produce a JMML-like MPN in mice 10–18.
Ptpn11 (Shp2), a ubiquitously expressed PTP, is implicated in multiple cell signaling 
processes, such as the Ras/Erk, PI3K/Akt, Jak/STAT, and NF-κB pathways that are activated 
by diverse growth factors, cytokines, insulin, growth hormones, and cell adhesion 
molecules 19–21. Shp2 is normally self-inhibited by hydrogen bonding of the backside loop 
of the N-terminal SH2 (N-SH2) domain with the deep pocket of the PTP domain 22, 23, and 
gets activated upon binding to signaling partners with phospho-tyrosine (pY) residues. 
Intriguingly, this phosphatase plays an overall positive role in transducing signals initiated 
from receptor kinases, particularly in the Ras pathway 19–21. The underlying signaling 
mechanisms are still not yet well understood. PTPN11 mutations found in JMML are 
concentrated in the N-SH2 domain and result in amino acid changes at the interphase 
between N-SH2 and PTP domains, disrupting the inhibitory intramolecular interaction, thus 
leading to increased Shp2 catalytic activity 7, 24. Although Ras hyperactivation is central in 
the pathogenesis of JMML, Ras effector or parallel pathways, such as PI3K/Akt signaling, 
have also been shown to contribute to the disease 25, 26. While activated Ras is able to 
activate PI3K by a direct interaction with the p110 catalytic subunit 27, cytokines, such as 
GM-CSF, can also activate PI3K in a Ras-independent manner via a Shp2-containing protein 
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complex including Gab2, Grb2, and PI3K regulatory subunit p85α 17, 28. In the present 
study, we sought to determine the role of the hematopoietic cell-specific scaffolding protein, 
Gab2, in gain-of-function Shp2-induced hyperactivation of PI3K/Akt and pathogenesis of 
MPN in vivo.
MATERIALS AND METHODS
Mice
Conditional knock-in mice (Ptpn11E76K neo/+) bearing the most common PTPN11 mutation 
found in JMML were generated in a previous study 16. Gab2+/− mice 29 were obtained from 
Dr. Toshio Hirano (Osaka University, Japan). Mx1-Cre+ transgenic mice were purchased 
from the Jackson Laboratory. Ptpn11E76K neo/+ mice were used to cross Mx1-Cre+ and 
Gab2+/− mice to generate Ptpn11E76K neo/+/Mx1-Cre+/Gab+/− mice. These mice were 
intercrossed to produce various types of mice for subsequent experiments. Mice of each 
genotype at the same age were numbered and randomly grouped for subsequent analyses. 
All mice were kept under specific pathogen–free conditions in the Division of Animal 
Resources at Emory University. All animal procedures complied with the National Institutes 
of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the 
Institutional Animal Care and Use Committee.
Retroviral vectors and retroviral transduction
Shp2 E76K and Shp2 D61Y cDNAs were subcloned into the murine stem-cell virus 
(MSCV)-based bicistronic retroviral vector, pMIEG3, in tandem with enhanced green 
fluorescent protein cDNA (EGFP). Ecotropic retroviral supernatants (pMIEG3, pMIEG3-
WT, pMIEG3-E76K, pMIEG3-D61Y) were prepared using Eco-Phoenix packaging cells by 
the Indiana University Vector Production Facility, as previously described 14.
Generation of BM-derived macrophages
BM cells were cultured in DMEM supplemented with 10% FBS and 20% L cell conditional 
medium (as a source of mouse colony-stimulating factor-1). Forty-eight hours later, 
nonadherent cells were collected and seeded into new tissue culture plates. After 5 to 7 days 
of culture, cells were confirmed to be macrophages as more than 90% of these cells were 
positive for Mac-1 and F4/80.
Flow cytometric analysis and cell sorting
Multiparameter FACS analyses were performed to determine populations of HSCs 
(Lineage−Sca-1+c-Kit+Flk2−CD48−CD150+), multipotent progenitor sub-population 1 
(MPP1, Lineage−Sca-1+c-Kit+Flk2−CD48−CD150−), MPP2 (Lineage−Sca-1+c-
Kit+Flk2−CD48+CD150+), and MPP3 (Lineage−Sca-1+c-Kit+Flk2−CD48+CD150−). 
Antibodies were purchased from eBiosciences, San Diego, CA, unless otherwise noted. BM 
cells freshly harvested from femurs and tibias were stained with biotin-labeled antibodies 
against mouse hematopoietic lineage markers: Mac-1 (M1/70), Gr-1 (RB6-8C5), Ter119 
(TER-119), CD3e (145-2C11), B220 (RA3-6B2), and subsequently stained with antibodies 
conjugated with various fluorochromes: streptavidin eFluor® 450, Sca-1-PE-Cy7 (D7, BD 
Biosciences, San Jose, CA), c-Kit-APC-eFlour780 (2B8), CD150-Alexa Fluor® 647 
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(TC15-12FF12.2, BD Biosciences), CD48-FITC (HM48-1), Flk2-PE (A2F10.1, BD 
Biosciences) for HSCs or MPPs. Specific cell populations were gated based on immune 
phenotypes for quantification or cell sorting. Fluorescence Minus One (FMO) was used for 
setting the gating on control samples. Flow cytometric analyses were performed on BD LSR 
II (BD Biosciences, San Jose). Cell sorting was conducted using BD FACSAria. Data were 
analyzed using FlowJo software (TreeStar, Ashland).
Apoptosis analysis
Fresh BM cells were stained with biotin-labeled antibodies against lineage markers (Gr-1, 
Mac-1, Ter119, CD3e, and B220) as described above, followed by staining with: streptavidin 
eFluor® 450, Sca-1-PE-Cy7 (D7), c-Kit-APC-eFlour780 (2B8). Cells were then incubated 
with Annexin V-FITC and 7-amino-actinomycin D (7-AAD) using Annexin V-FITC 
apoptosis detection kit I (BD Biosciences, San Jose, CA). Apoptotic (Annexin V+) cells in 
the gated Lineage−Sca-1+c-Kit+ (LSK) cell population were quantified by FACS.
Colony-forming unit assay
For the myeloid progenitor assay, freshly harvested mouse BM nucleated cells (2×104 
cells/mL) or patient biopsy marrow cells (1×104 cells/mL) were assayed for colony forming 
units (CFUs) in 0.9% methylcellulose IMDM medium containing 30% FBS, glutamine 
(10−4 M), β-mercaptoethanol (3.3×10−5 M), and IL-3 or GM-CSF at the indicated 
concentrations. After 7 days (mouse cells) or 14 days (human cells) of culture at 37 °C in a 
humidified 5% CO2 incubator, myeloid colonies (CFU-GM and CFU-M) were counted 
under an inverted microscope.
Rapamycin treatment
Rapamycin (LC Laboratories, Woburn) was dissolved in 100% ethanol at a concentration of 
10 mg/mL, diluted in 5% Tween-80 and 5% PEG-400, and administered by intraperitoneal 
injections at 10 mg/kg body weight, once daily for 12–14 weeks starting on the following 
day after Ptpn11E76K/+/Mx1-Cre+ mice were administered pI-pC (to induce the 
Ptpn11E76K/+ mutation).
Statistical analysis
All experiments were repeated two to three times with the indicated numbers of mice. Data 
are presented as mean±S.D. Statistical significance was determined using unpaired two-
tailed Student’s t test. P values < 0.05 were considered to be statistically significant.
RESULTS
Interaction of Shp2 with Gab2 is enhanced by leukemia-associated Ptpn11 mutations
The hallmark of JMML is Ras hyperactivation and the hypersensitivity of myeloid 
progenitors to cytokines 1, 2. However, signaling partners that mediate the effects of Ptpn11 
mutations in this disease have not been well characterized. We hypothesized that the 
hematopoietic specific scaffolding protein, Gab2, contributes to Ptpn11 mutation-induced 
hyperactivation of Ras and PI3K/Akt signaling. To investigate this hypothesis, we 
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transduced BM low density mononuclear cells with wildtype (WT) Shp2 or leukemia-
associated mutants Shp2 E76K and Shp2 D61Y. As shown in Figure 1A, in response to GM-
CSF stimulation, tyrosine phosphorylation of Gab2 was significantly increased in mutant 
Shp2-expressing cells as compared to WT Shp2-expressing cells. Moreover, interactions 
between mutant Shp2 and Gab2 were enhanced by Shp2 mutations. We also generated BM-
derived macrophages from Ptpn11E76K conditional knock-in mice (Ptpn11E76K/+/Mx1-
Cre+), which developed JMML-like MPN following induction of the Ptpn11E76K 
mutation 16, and determined the impact of the Ptpn11E76K mutation on GM-CSF-induced 
signaling. In response to GM-CSF stimulation, activation of Erk, Jak2, and Stat5 was 
increased in Ptpn11E76K/+ mutant cells (Figure 1B). Previously studies have shown that 
Gab2 plays an important role in the PI3K/Akt pathway by interacting with the p85 subunit 
of PI3K 28; we therefore took a closer look at this pathway. As shown in Figure 1C, 
activation of Akt was increased in Ptpn11E76K/+ cells. Furthermore, activities of the 
downstream mTOR pathway were also enhanced as evidenced by elevated phosphorylation 
levels of S6 and 4E-BP1. These observations together indicate that increased interaction of 
mutated Shp2 with Gab2 might mediate the detrimental effects of Ptpn11 mutations on 
cytokine signaling.
Important role of Gab2 in mediating the pathogenic effects of the Ptpn11E76K mutation
To further test the role of Gab2 in the pathogenesis and maintenance of MPN induced by 
Ptpn11 mutations, we generated Ptpn11E76K/+/Gab2−/− double mutant mice from 
Ptpn11E76K knock-in 16 and Gab2 knockout (Gab2+/−) 29 mice, and monitored disease 
development and progression in these double mutants. This test is especially interesting 
given that steady state hematopoiesis in Gab2 deficient mice is not significantly changed 
although Gab2-depleted stem cells showed decreased repopulation capabilities in 
competitive repopulation assays 30. Compared to Ptpn11E76K/+ single mutant mice, gross 
health signs of Ptpn11E76K/+/Gab2−/− double mutants were significantly improved. MPN 
phenotypes, such as elevated white blood cell (WBC) counts (Supplemental Table 1) and 
splenomegaly were attenuated in double mutants (Figure 2A). Overproduction of mature 
myeloid cells (Mac-1+/Gr-1+) and immature myeloid cells (Mac-1+/Gr-1−) was largely 
corrected (Figure 2B). In addition, myeloid cell infiltration in the liver (Figure 2C), lung, 
and kidney (data not shown) was diminished in double mutant mice. Histopathological 
examination confirmed that excessive proliferation of myeloid cells in the BM and spleen 
was reduced and myeloid cell infiltration in non-hematopoietic organs (liver, lung, and 
kidney) was significantly decreased in these double mutant mice (Supplemental Figure 1). 
More importantly, only 11% of Ptpn11E76K/+/Gab2−/− mice progressed into acute leukemias 
as opposed to 63% in Ptpn11E76K/+ single mutant mice during 12 month follow-up (Figure 
2D), and the overall survival of double mutants was prolonged (Figure 2E). These 
observations suggest that Gab2 plays an important role in mediating the pathogenic effects 
of the Ptpn11E76K mutation in the development and progression of MPN.
MPN is known to be a clonal stem cell disorder; to further determine whether the rescue 
effects of Gab2 deletion occurred at the stem cell level, we analyzed HSCs in double 
mutants and compared to those in Ptpn11E76K/+ single mutants. The frequency and absolute 
number of HSCs in the BM of Ptpn11E76K/+ mice were reduced due to the hyperactivation 
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and exhaustion of the reserve capacity, consistent with previous findings 16. The frequency 
and absolute number (Supplemental Figure 2A–2C) of HSCs at steady state in 
Ptpn11E76K/+/Gab2−/− mice were not significantly changed as compared to Ptpn11E76K/+ 
mice. However, apoptosis of hematopoietic stem/progenitor cells (Lineage−Sca-1+c-Kit+, 
LSK cells) in Ptpn11E76K/+/Gab2−/− double mutant mice was nearly restored to the 
physiological level (Supplemental Figure 2D and 2E) as opposed to significantly reduced 
apoptosis in Ptpn11E76K/+ single mutant mice.
The myeloid malignancy induced by Ptpn11 mutations is characterized by cytokine 
hypersensitivity of myeloid progenitors 1, 2; we therefore assessed the sensitivity of myeloid 
progenitors to GM-CSF and IL-3 in Ptpn11E76K/+/Gab2−/− double and Ptpn11E76K/+ single 
mutant mice. As demonstrated in Figure 3A and Supplemental Figure 3, Gab2 depletion in 
Ptpn11E76K/+ progenitors significantly decreased the hypersensitivity to GM-CSF and IL-3. 
Moreover, cytokine-independent baseline colony formation of myeloid progenitors was 
abolished in Ptpn11E76K/+/Gab2−/− double mutants. To further verify these results, we sorted 
stem cell-enriched LSK cells and assessed their responses to cytokine-induced 
differentiation. Compared to Ptpn11E76K/+ cells, myeloid differentiation/expansion (Figure 
3B and Supplemental Figure 4 and Figure 3C) of Ptpn11E76K/+/Gab2−/− cells in the presence 
of IL-3 was significantly decreased. These data together suggest that Gab2 depletion 
attenuates Ptpn11E76K/+ mutation-induced myeloid malignancy mainly by decreasing the 
cytokine sensitivity of myeloid progenitors.
Gab2 depletion attenuates the detrimental effects of the Ptpn11E76K mutation on cytokine 
signaling
The signaling mechanisms underlying the effects of Gab2 deletion on the pathogenesis of 
Ptpn11E76K mutation-induced MPN were determined. Gab2 is an important scaffolding 
protein in cytokine signaling pathways 28. We generated BM-derived macrophages from 
Ptpn11E76K/+ single and Ptpn11E76K/+/Gab2−/− double mutant mice and analyzed GM-CSF 
signaling in these cells. As shown in Figure 4A, in response to GM-CSF stimulation, 
activation of Erk and Stat5 was not significantly changed in the double mutant cells. 
However, Akt activity determined by phosphorylation of Serine473 and Threonine308 was 
decreased in the double mutant cells as compared to that in Ptpn11E76K/+ single mutant 
cells, suggesting that the rescue effects of Gab2 deficiency on Ptpn11E76K mutation-
associated aberrant hematopoietic cell development might be attributable to the reduced Akt 
pathway. To verify this notion, we analyzed the downstream mTOR signaling in primary 
MPN cells isolated from diseased Ptpn11E76K/+ mice and Ptpn11E76K/+/Gab2−/− double 
mutants. As shown in Figure 4B, phosphorylation of S6 and 4E-BP1 in the MPN cells of 
Ptpn11/Gab2 double mutants was reduced relative to that in Ptpn11E76K/+ single mutant 
mice.
Therapeutic effects of Rapamycin for the MPN induced by the Ptpn11E76K mutation
Given that MPN was ameliorated in Ptpn11E76K/+/Gab2−/− double mutant mice and that the 
mTOR signaling activities were decreased in double mutant cells, we reasoned that targeting 
the mTOR pathway might be effective in controlling Ptpn11 activating mutation-induced 
myeloid malignancy. To test this hypothesis, we treated Ptpn11E76K knock-in mice with 
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Rapamycin, a potent and selective inhibitor of mTOR, and monitored disease phenotypes in 
these mice. As shown in Figure 5A, treatment of Rapamycin at an optimal dosage 
significantly decreased WBC counts in diseased Ptpn11E76K/+ mice. Importantly, control 
mice did not show overt hematopoietic suppression, highlighting a potential therapeutic 
index. Splenomegaly was also reduced in treated Ptpn11E76K/+ mice (Figure 5B). 
Furthermore, cytokine hypersensitivity of myeloid progenitors was abolished in Rapamycin-
treated Ptpn11E76K/+ mice (Figure 5C and Supplemental Figure 5), and the colonies derived 
in colony assays were much smaller (Figure 5D). Additionally, we analyzed the mTOR 
signaling pathway in the BM cells isolated from Rapamycin-treated Ptpn11E76K/+ and 
control mice, and found that phosphorylation of S6 and 4E-BP1 was barely detectable 
(Figure 5E). These results collectively demonstrate therapeutic effects of Rapamycin in the 
mouse model of Ptpn11 mutation-associated myeloid malignancy.
Rapamycin corrects the hypersensitive growth pattern of JMML patient cells with the 
PTPN11E76K mutation
BM cells from patients with JMML display a characteristic hypersensitive growth pattern, 
resulting in greater production of granulocyte-macrophage colonies in response to GM-
CSF 1, 2. We next determined whether Rapamycin could inhibit colony formation and 
proliferation of JMML patient cells with PTPN11 activating mutations at an optimal dosage 
that does not inhibit normal marrow progenitors. As shown in Figure 6A, GM-CSF-induced 
colony formation of myeloid blasts from JMML patients with PTPN11 activating mutations 
was more sensitive to Rapamycin than healthy donor progenitors. Consistent with this data, 
PTPN11 mutation-positive JMML cells cultured in GM-CSF-containing liquid medium was 
also more sensitive than healthy donor BM cells to the inhibition by Rapamycin at 2.5 nM 
(Figure 6B). The finding that Rapamycin is able to overcome the dominant effects of 
oncogenic mutant SHP2 in primary human leukemia cells support for a potential therapeutic 
benefit of this drug in PTPN11 mutation-associated JMML.
DISCUSSION
Hyperactivation of the Ras/Erk signaling pathway is known to underlie the pathogenesis of 
JMML 3–5. Interestingly, the PI3K/Akt signaling pathway is also dysregulated in this 
disease, and this can be dependent and independent of the Ras pathway 25. PTPN11 gain-of-
function mutations are associated with 35% of JMML. However, it has not been well 
characterized how PTPN11 mutations lead to Ras-dependent and/or independent 
hyperactivation of the PI3K/Akt signaling. In this study, we demonstrate that the interaction 
between JMML-associated mutant Shp2 E76K and Gab2, a scaffolding protein important for 
cytokine-induced PI3K/Akt signaling 28, was enhanced, and that the mTOR pathway was 
highly activated in Ptpn11E76K/+ leukemic cells. Importantly, MPN induced by the 
Ptpn11E76K/+ mutation was markedly attenuated in Ptpn11E76K/+/Gab2−/− double mutant 
mice. These observations indicate that Gab2 may play a key role downstream of mutated 
Shp2 in mediating the leukemogenic effects of Ptpn11 mutations. Ptpn11 gain-of-function 
mutations appear to disturb cytokine signaling through multiple mechanisms. These 
mutations result in increased catalytic activity of Shp2 7, 24 and also enhanced binding to 
signaling partners 13, 31 due to the disruption of the inhibitory intramolecular interaction and 
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the conformational change of the Shp2 protein. The gain-of-function mutations of Shp2 
enhance Ras activity likely through elevated catalytic activity of Shp2 since Shp2 catalytic 
activity plays a positive role in the Ras pathway although the detailed mechanism is still 
elusive 19–21. Hyperactivation of Ras leads to increased PI3K/Akt signaling due to the well-
established crosstalk between the two pathways 27. In addition, mutated Shp2 may directly 
induce increased PI3K/Akt signaling through enhanced binding with the scaffolding protein 
Gab2 that couples the p85 subunit of PI3K to the cytokine receptor 28 and the plasma 
membrane. In this signaling complex, mutant Shp2 may serve as an adaptor protein 
independent of its catalytic activity. Indeed, this phosphatase can function in cytokine 
signaling in both catalytically-dependent and –independent manners 32.
Another important finding is this study is the pre-clinical therapeutic efficacy of Rapamycin 
in the mouse model of Ptpn11 mutation-induced MPN. We showed that administration of 
Rapamycin at a tolerable dose significantly alleviated the MPN burden in Ptpn11E76K/+ 
mice, and also that this drug at a low dose selectively suppressed PTPN11 mutation-positive 
JMML patient cells over healthy donor cells in vitro. Given that Rapamycin is a clinically-
used immunosuppressant and anti-cancer drug for adult patients, this drug may be further 
developed, used alone or in combination with MEK inhibitors that target the hyperactivated 
Ras/Erk pathway, as a novel therapeutic strategy for PTPN11 mutation-associated JMML. 
This notion is also supported by the previous observation that PTEN expression, a negative 
regulator of PI3K/Akt/mTOR signaling, frequently was reduced in primary JMML patient 
samples 33 although the gene mutation status of the JMML specimens was not determined. 
The elevated Ras-independent activation of PI3/Akt/mTOR signaling may be specific for 
Ptpn11 mutation-induced MPN since this is caused by enhanced interaction of mutated Shp2 
with Gab2. It remains to be determined whether the PI3/Akt/mTOR pathway may also be an 
effective target for the treatment of other subtypes of JMML associated with the RAS, NF1, 
or CBL mutations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The Ptpn11E76K mutation enhances cytokine-induced PI3K/Akt/mTOR signaling
(A) BM progenitors transduced with WT Shp2, Shp2 D61Y, Shp2 E76K, or control vector 
were sorted and differentiated to macrophages, which were starved in serum and cytokine-
free medium for 48 hours and then stimulated with GM-CSF (50 ng/mL) for as long as 60 
minutes. Protein extracts were prepared and immunoprecipitated with anti-Gab2 antibody 
followed by anti-pY immunoblotting. Blots were stripped and reprobed with anti-Shp2 and 
then anti-Gab2 antibodies. (B) BM-derived macrophages were generated from 
Ptpn11E76K/+/Mx1-Cre+ and Ptpn11+/+/Mx1-Cre+ mice 6–8 weeks following pI-pC 
administration. These cells were starved and then stimulated with GM-CSF (50 ng/mL) for 
the indicated periods of time. Whole cell lysates were prepared. Levels of p-ERK, p-Jak2, 
and p-Stat5 were determined by immunoblotting analyses. Blots were striped and reprobed 
with anti-ERK, anti-Jak2, anti-Stat5, and anti-Shp2 antibodies to check for protein loading. 
(C) The cell lysates were also examined for levels of p-AKT, p-mTOR, p-S6, and p-4E-BP1 
by immunoblotting analyses. Blots were stripped and reprobed with anti-AKT and anti-
mTOR antibodies to check for protein loading. Experiments were repeated three times with 
similar results obtained in each.
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Figure 2. Development and progression of Ptpn11E76K/+ mutation-induced MPN are attenuated 
by deletion of Gab2
Ptpn11+/+/Mx1-Cre+/Gab2+/+, Ptpn11+/+/Mx1-Cre+/Gab2−/−, Ptpn11E76K/+/Mx1-Cre+/
Gab2+/+, and Ptpn11E76K/+/Mx1-Cre+/Gab2−/− mice were analyzed 10~14 weeks after pI-
pC administration. Spleen weights (A) (n=5–10/group), percentages of Mac-1+/Gr-1+ and 
Mac-1+/Gr-1− cells in the BM, spleen, peripheral blood (B), and liver (C) (n=4–10/group) 
were determined. Data are shown as mean±S.D. (D) A cohort of pI-pC-administered 
Ptpn11E76K/+/Mx1-Cre+/Gab2+/+ (n=27) and Ptpn11E76K/+/Mx1-Cre+/Gab2−/− (n=18) mice 
were monitored for acute leukemia progression for 12 months as we previously described 16. 
The percentages of the mice that progressed to acute leukemias were documented. (E) 
Kaplan–Meier survival curves of Ptpn11E76K/+/Mx1-Cre+/Gab2+/+ and Ptpn11E76K/+/Mx1-
Cre+/Gab2−/− mice.
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Figure 3. Depletion of Gab2 corrects the hypersensitive growth pattern of Ptpn11E76K/+ myeloid 
progenitors
(A) BM cells (2×104 cells/mL) freshly harvested from the mice with the indicated genotypes 
(n=3/group) were assessed by CFU assays 8 weeks after pI-pC administration with a range 
of GM-CSF concentrations. (B) BM-derived macrophages were generated from the mice 
with the indicated genotypes (n=3/group) and cultured in DMEM supplemented with 10% 
FBS and 20% L cell conditional medium for 3 days. Cell growth rates were determined 
using a One Solution Cell Proliferation Assay kit. (C) LSK (Lineage−Sca-1+c-Kit+) cells 
were sorted from the mice with the indicated genotypes (n=6/group) and cultured in the 
presence of IL-3 (2 ng/mL). After 7 days of in vitro culture, percentages of myeloid 
(Mac-1+/Gr-1+) cells differentiated from LSK cells were assayed by FACS. Three 
independent experiments were performed with similar results obtained in each. Data shown 
are mean±S.D. from one experiment.
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Figure 4. Gab2 deletion reverses the enhanced PI3K/Akt/mTOR signaling caused by the 
Ptpn11E76K/+ mutation
(A) BM-derived macrophages generated from pI-pC administered Ptpn11E76K/+/Mx1-Cre+/
Gab2+/+ and Ptpn11E76K/+/Mx1-Cre+/Gab2−/− mice were starved in serum and cytokine-free 
medium for 48 hours and then stimulated with GM-CSF (50 ng/mL) for the indicated 
periods of time. Whole cell lysates were prepared. Levels of p-Erk, p-Akt, and p-Stat5 were 
determined by immunoblotting analyses. Blots were striped and reprobed with anti-Erk, 
anti-Akt, anti-Shp2, and anti-Gab2 antibodies to check for protein loading and Gab2 
deletion efficiency. Three independent experiments with three pairs of mice were performed. 
Similar results were obtained in each. (B) MPN cell lysates prepared from Ptpn11E76K/+/
Mx1-Cre+/Gab2+/+ and Ptpn11E76K/+/Mx1-Cre+/Gab2−/− mice 10 weeks after pI-pC 
administration when MPN was fully developed were immunoblotted with p-S6 and p-4E-
BP1. Shp2 levels in the tissue lysates were examined by anti-Shp2 immunoblotting. Each 
lane represents an individual mouse.
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Figure 5. Rapamycin treatment mitigates MPN in Ptpn11E76K/+ mice
(A) WBC counts in the peripheral blood of Ptpn11E76K/+/Mx1-Cre+ mice were determined 
before and after 12–14 weeks of treatment with Rapamycin (10 mg/kg body weight, once 
daily) or the vehicle (n=5/group). (B) Spleen weights were determined after 12–14 weeks of 
treatment with Rapamycin or vehicle. (C) BM cells were harvested from Ptpn11+/+/Mx1-
Cre+ and Ptpn11E76K/+/Mx1-Cre+ mice after 12–14 weeks of treatment with Rapamycin or 
vehicle. These cells were assessed by CFU assays at the indicated GM-CSF concentrations. 
Experiments were performed three times with similar results obtained in each. Data shown 
are mean±S.D. from one experiment in triplicates. (D) Representative colonies growing in 
the medium containing GM-CSF (0.1 ng/mL) are shown. The average number of the cells 
per colony was determined by dividing the total number of the cells harvested from each 
plate with the number of the colonies in that plate (n=3/group). Experiments were performed 
in three pairs of mice with similar results obtained in each. Data shown are mean±S.D. from 
one experiment in triplicates. (E) Spleen lysates were prepared from Ptpn11+/+/Mx1-Cre+ 
and Ptpn11E76K/+/Mx1-Cre+ mice after 12–14 weeks of treatment with Rapamycin or 
vehicle. Levels of p-S6, p-4E-BP1, and Shp2 were determined by immunoblotting analyses. 
Each lane represents an individual mouse.
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Figure 6. Rapamycin abrogates cytokine-induced overgrowth of JMML patient cells with the 
PTPN11E76K mutation
(A) BM cells (1×104 cells/mL) from five JMML patients with the indicated PTPN11 
mutations and three normal donors were plated in methylcellulose medium containing GM-
CSF (1.0 ng/mL) and Rapamycin at the indicated concentrations. Colonies were enumerated 
14 days later and normalized against the number of the colonies derived without Rapamycin 
treatment. (B) BM cells from five JMML patients with the indicated PTPN11 mutations and 
normal donors were cultured in IMDM containing GM-CSF (1.0 ng/mL) and Rapamycin 
(2.5 nM) or vehicle. Cell numbers were determined using the One Solution Cell 
Proliferation Assay kit. Data shown are mean±S.D. of all samples tested.
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